Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Inclusion Criteria:

1. ≥ 40 years of age prior to screening

2. IPF diagnosis ≤ 7 years prior to screening

3. FVCpp ≥ 45%

4. Diffusing capacity for carbon monoxide percent predicted (hemoglobin-adjusted) ≥ 30%and < 90%

5. Current treatment for IPF with background therapy is allowed, if at a stable dosefor ≥ 12 weeks prior to screening

6. If not currently receiving treatment for IPF (either treatment naïve or discontinuedprior treatment), participant must not have taken background therapy for at least 8weeks prior to screening

Exclusion Criteria:

1. Receiving pharmacologic therapy for pulmonary hypertension

2. Self-reported smoking of any kind (not limited to tobacco)

3. History of malignancy within the past 5 years or ongoing malignancy other than basalcell carcinoma, resected noninvasive cutaneous squamous cell carcinoma, or treatedcervical carcinoma in situ

4. Hepatic impairment or end-stage liver disease

5. Renal impairment or end-stage kidney disease requiring dialysis

6. Pregnant or lactating female participant

7. Uncontrolled systemic arterial hypertension

8. Receiving any unapproved or investigational agent intended for treatment of fibrosisin IPF

9. Prior administration of bexotegrast

10. Likely to have lung transplantation during the study (being on transplantation listis not an exclusion)

11. Forced expiratory volume in the first second (FEV1)/FVC ratio <0.7 at screening

12. Clinical evidence of active infection, including, but not limited to bronchitis,pneumonia, or sinusitis that can affect FVC measurement during screening or atrandomization

13. Known acute IPF exacerbation, or suspicion by the Investigator of such, 6 monthsprior to screening